title: Protein cross-linking as a novel mechanism of action of a ubiquitin-activating enzyme inhibitor with anti-tumor activity.
abstract: Ubiquitin-activating enzyme 1 (UBE1) is a critical regulator of the ubiquitination cycle and its targeted inhibition may be an appropriate therapeutic strategy as tumor cells are reported to have increased dependence on protein ubiquitination. PYR-41 is a small molecule with previously described UBE1 inhibitory activity. PYR-41 blocks ubiquitination reactions but paradoxically leads to the accumulation of high MW ubiquitinated proteins. Detailed evaluation of PYR-41 activity demonstrated that PYR-41 inhibited UBE1 activity but also had equal or greater inhibitory activity against several deubiquitinases (DUBs) in intact cells and purified USP5 in vitro. Both UBE1 and DUB inhibition were mediated through PYR-41-induced covalent protein cross-linking which paralleled the inhibition of the target proteins enzymatic activity. PYR-41 also mediated cross-linking of specific protein kinases (Bcr-Abl, Jak2) to inhibit their signaling activity. Chemical reactivity modeling provided some insight into the cross-linking potential and partial target selectivity of PYR-41. Overall, our results suggest a broader range of targets and a novel mechanism of action for this UBE1 inhibitor. In addition, since PYR-41-related compounds have demonstrated anti-tumor activity in animal studies, partially selective protein cross-linking may represent an alternate approach to affect signal transduction modules and ubiquitin cycle-regulatory proteins for cancer therapy.
authors.affiliation: Department of Internal Medicine, Division of Hematology-Oncology, University of Michigan, Ann Arbor, MI, USA.
authors.forename: Vaibhav
authors.initials: V
authors.lastname: Kapuria
authors.forename: Luke F
authors.initials: LF
authors.lastname: Peterson
authors.forename: H D Hollis
authors.initials: HD
authors.lastname: Showalter
authors.forename: Paul D
authors.initials: PD
authors.lastname: Kirchhoff
authors.forename: Moshe
authors.initials: M
authors.lastname: Talpaz
authors.forename: Nicholas J
authors.initials: NJ
authors.lastname: Donato
mesh_terms: D000970:Antineoplastic Agents / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology; D001565:Benzoates / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology; D003432:Cross-Linking Reagents / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D005663:Furans / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology; D057809:HEK293 Cells; D006801:Humans; D020014:K562 Cells; D011720:Pyrazoles / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology; D044764:Ubiquitin-Activating Enzymes / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D057149:Ubiquitinated Proteins / Q000737:chemistry / Q000378:metabolism*
chemical_list: C523934:4(4-(5-nitro-furan-2-ylmethylene)-3,5-dioxo-pyrazolidin-1-yl)-benzoic acid ethyl ester; D000970:Antineoplastic Agents; D001565:Benzoates; D003432:Cross-Linking Reagents; D004791:Enzyme Inhibitors; D005663:Furans; D011720:Pyrazoles; D057149:Ubiquitinated Proteins; D044764:Ubiquitin-Activating Enzymes